New aspects of pharmacological nephroprotection
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Current estimates forecast that chronic kidney diseases will be the fifth most common cause of death worldwide by 2040. The prevalence of chronic renal diseases increases with age and, in many countries, affects patients with overweight, diabetes and hypertension. The primary objective of the treatment of chronic renal diseases is the delay of disease progression. Established markers for the deterioration of renal function include glomerular filtration rate and albuminuria. Pharmacological blockade of the renin-angiotensin-aldosterone system (RAAS) by angiotensin-converting enzyme inhibitors (ACE) or angiotensin receptor blockers (ARB) represents the cornerstone of drug-related nephroprotection. Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend the use of ACEI or ARB for diabetic and non-diabetic patients with moderate and heavy albuminuria. In recent years, sodium-glucose linked transporter 2 inhibitors (SGLT-2 ) have been established in the field of cardio- and nephroprotection. Their protective effects occur regardless of blood sugar reduction. Current data suggest that the use of SGLT‑2 inhibitors will soon be part of therapy in non-diabetic kidney disease. One of the first drugs in this substance class, dapagliflozin, is already approved in Germany for the treatment of chronic renal diseases in adults with and without type 2 diabetes.
| Errataetall: |
ErratumIn: Inn Med (Heidelb). 2022 Oct 20;:. - PMID 36264320 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Innere Medizin (Heidelberg, Germany) - 63(2022), 11 vom: 11. Nov., Seite 1200-1207 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Neue Aspekte der medikamentösen Nephroprotektion |
|---|
| Beteiligte Personen: |
Beimler, Jörg [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.10.2022 Date Revised 24.01.2023 published: Print-Electronic ErratumIn: Inn Med (Heidelb). 2022 Oct 20;:. - PMID 36264320 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00108-022-01297-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339100451 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339100451 | ||
| 003 | DE-627 | ||
| 005 | 20231226002142.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00108-022-01297-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339100451 | ||
| 035 | |a (NLM)35380212 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Beimler, Jörg |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New aspects of pharmacological nephroprotection |
| 246 | 3 | 3 | |a Neue Aspekte der medikamentösen Nephroprotektion |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2022 | ||
| 500 | |a Date Revised 24.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Inn Med (Heidelb). 2022 Oct 20;:. - PMID 36264320 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Current estimates forecast that chronic kidney diseases will be the fifth most common cause of death worldwide by 2040. The prevalence of chronic renal diseases increases with age and, in many countries, affects patients with overweight, diabetes and hypertension. The primary objective of the treatment of chronic renal diseases is the delay of disease progression. Established markers for the deterioration of renal function include glomerular filtration rate and albuminuria. Pharmacological blockade of the renin-angiotensin-aldosterone system (RAAS) by angiotensin-converting enzyme inhibitors (ACE) or angiotensin receptor blockers (ARB) represents the cornerstone of drug-related nephroprotection. Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend the use of ACEI or ARB for diabetic and non-diabetic patients with moderate and heavy albuminuria. In recent years, sodium-glucose linked transporter 2 inhibitors (SGLT-2 ) have been established in the field of cardio- and nephroprotection. Their protective effects occur regardless of blood sugar reduction. Current data suggest that the use of SGLT‑2 inhibitors will soon be part of therapy in non-diabetic kidney disease. One of the first drugs in this substance class, dapagliflozin, is already approved in Germany for the treatment of chronic renal diseases in adults with and without type 2 diabetes | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Dapagliflozin | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Renal insufficiency, chronic | |
| 650 | 4 | |a Renin-angiotensin-aldosterone system | |
| 650 | 4 | |a Sodium-glucose transporter 2 inhibitors | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Innere Medizin (Heidelberg, Germany) |d 2022 |g 63(2022), 11 vom: 11. Nov., Seite 1200-1207 |w (DE-627)NLM33707271X |x 2731-7099 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:11 |g day:11 |g month:11 |g pages:1200-1207 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00108-022-01297-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 11 |b 11 |c 11 |h 1200-1207 | ||